

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0 Revision Date: 20.11.2025 SDS Number: 59271-00026 Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

SECTION 1. IDENTIFICATION

Product name : Doravirine Formulation

Manufacturer or supplier's details

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

|| Not a hazardous substance or mixture.

GHS label elements

|| No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 20 -< 30
Doravirine	1338225-97-0	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0	Revision Date: 20.11.2025	SDS Number: 59271-00026	Date of last issue: 06.07.2024 Date of first issue: 16.02.2015
----------------	------------------------------	----------------------------	---

	advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	: No special precautions are necessary for first aid responders.
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Halogenated compounds Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment.

SAFETY DATA SHEET



Doravirine Formulation

Version
9.0

Revision Date:
20.11.2025

SDS Number:
59271-00026

Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

- : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures

- : Static electricity may accumulate and ignite suspended dust causing an explosion.

Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation
Advice on safe handling

- : Use only with adequate ventilation.

- : Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Minimize dust generation and accumulation.

Keep container closed when not in use.

Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage

- : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid

- : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	CMP	10 mg/m ³	AR OEL
Doravirine	1338225-97-0	TWA	10 mg/m ³	ACGIH
		TWA	500 ug/m ³ (OEB2)	Internal

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0	Revision Date: 20.11.2025	SDS Number: 59271-00026	Date of last issue: 06.07.2024 Date of first issue: 16.02.2015
----------------	------------------------------	----------------------------	---

Magnesium stearate	557-04-0	CMP	10 mg/m ³	AR OEL
Further information: A4 - Not classifiable as a human carcinogen				
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection
Material

: Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
Hygiene measures : Work uniform or laboratory coat.
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Color	: off-white
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0 Revision Date: 20.11.2025 SDS Number: 59271-00026 Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity :

Not classified as a reactivity hazard.

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0 Revision Date: 20.11.2025 SDS Number: 59271-00026 Date of last issue: 06.07.2024 Date of first issue: 16.02.2015

Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Doravirine:

Acute oral toxicity : LD50 (Rat): > 750 mg/kg
Remarks: No mortality observed at this dose.
(Rat): Method: Phototoxicity
Remarks: No evidence of phototoxicity was observed
LD50 (Dog): > 1.000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 450 mg/kg
Remarks: No mortality observed at this dose.

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0 Revision Date: 20.11.2025 SDS Number: 59271-00026 Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

II

Skin corrosion/irritation

Not classified based on available information.

Components:

Doravirine:

||| Remarks : No data available

Magnesium stearate:

||| Species : Rabbit
||| Result : No skin irritation
||| Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Doravirine:

||| Remarks : No data available

Magnesium stearate:

||| Species : Rabbit
||| Result : No eye irritation
||| Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Doravirine:

||| Remarks : No data available

Magnesium stearate:

||| Test Type : Maximization Test
||| Routes of exposure : Skin contact
||| Species : Guinea pig
||| Method : OECD Test Guideline 406
||| Result : negative
||| Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0	Revision Date: 20.11.2025	SDS Number: 59271-00026	Date of last issue: 06.07.2024 Date of first issue: 16.02.2015
----------------	------------------------------	----------------------------	---

Components:

Cellulose:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Doravirine:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative

Magnesium stearate:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
	Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

Doravirine FormulationVersion
9.0Revision Date:
20.11.2025SDS Number:
59271-00026Date of last issue: 06.07.2024
Date of first issue: 16.02.2015**Doravirine:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	6 Months
Result	:	negative
Remarks	:	No significant adverse effects were reported

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on fetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

Doravirine:

Effects on fertility	:	Test Type: Fertility Species: Rat, male and female Fertility: NOAEL: 450 mg/kg body weight Result: No effects on fertility.
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 450 mg/kg body weight Result: No adverse effects.
		Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No adverse effects.

Magnesium stearate:

Effects on fertility	:	Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on fetal development	:	Test Type: Embryo-fetal development

SAFETY DATA SHEET



Doravirine Formulation

Version
9.0

Revision Date:
20.11.2025

SDS Number:
59271-00026

Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
NOAEL : >= 9.000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Doravirine:

Species : Rat
NOAEL : 450 mg/kg
Application Route : Oral
Exposure time : 6 Months
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : > 450 mg/kg
Application Route : Oral
Exposure time : 3 Months
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : > 1.000 mg/kg
Application Route : Oral
Exposure time : 9 Months
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Doravirine FormulationVersion
9.0Revision Date:
20.11.2025SDS Number:
59271-00026Date of last issue: 06.07.2024
Date of first issue: 16.02.2015**Experience with human exposure****Components:****Doravirine:**

Ingestion	: Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression
-----------	--

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

Doravirine:

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): 9,1 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 5,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
	NOEC (Pseudokirchneriella subcapitata (green algae)): 5,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 1 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0,38 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms	: EC50: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition

Doravirine FormulationVersion
9.0Revision Date:
20.11.2025SDS Number:
59271-00026Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Doravirine:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 2 %
Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0 Revision Date: 20.11.2025 SDS Number: 59271-00026 Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

Bioaccumulative potential

Components:

Doravirine:

Partition coefficient: n-octanol/water : log Pow: 2,08

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Doravirine:

Distribution among environmental compartments : log Koc: 2,86

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

MERCOSUR

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SAFETY DATA SHEET



Doravirine Formulation

Version 9.0 Revision Date: 20.11.2025 SDS Number: 59271-00026 Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 20.11.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

AR OEL : Argentina. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average

AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization

SAFETY DATA SHEET



Doravirine Formulation

Version
9.0

Revision Date:
20.11.2025

SDS Number:
59271-00026

Date of last issue: 06.07.2024
Date of first issue: 16.02.2015

ganization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8